Structure-Based Drug Design of Novel Indazole/Indolinone-Based Biaryl Derivatives as Oral IRAK4 Inhibitors for the Treatment of Inflammatory Diseases.
Pathological inflammation in multiple diseases arises from dysregulated innate immune signaling, wherein the interleukin-1 receptor-associated kinase 4 (IRAK4) acts as a critical node that mediates pro-inflammatory cascades and cytokine release downstream of toll-like and interleukin-1 receptors (TLR/IL-1R). Consequent...